KPTI PE Ratio & Valuation,Is KPTI Overvalued

KPTI Relative Valuation

KPTI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KPTI is overvalued; if below, it's undervalued.

Historical Valuation

Karyopharm Therapeutics Inc (KPTI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.83 is considered Undervalued compared with the five-year average of -2.24. The fair price of Karyopharm Therapeutics Inc (KPTI) is between 201.55 to 229.15 according to relative valuation methord. Compared to the current price of 6.95 USD , Karyopharm Therapeutics Inc is Undervalued By 96.55%.

Relative Value

Fair Zone

201.55-229.15

Current Price：6.95

96.55%

Undervalued

-0.96

0.00

EV/EBITDA

Karyopharm Therapeutics Inc. (KPTI) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.35. The thresholds are as follows: Strongly Undervalued below -6.23, Undervalued between -6.23 and -4.29, Fairly Valued between -0.41 and -4.29, Overvalued between -0.41 and 1.54, and Strongly Overvalued above 1.54. The current Forward EV/EBITDA of 0.00 falls within the Overvalued range.

-3.46

EV/EBIT

Karyopharm Therapeutics Inc. (KPTI) has a current EV/EBIT of -3.46. The 5-year average EV/EBIT is -3.30. The thresholds are as follows: Strongly Undervalued below -5.89, Undervalued between -5.89 and -4.60, Fairly Valued between -2.01 and -4.60, Overvalued between -2.01 and -0.72, and Strongly Overvalued above -0.72. The current Forward EV/EBIT of -3.46 falls within the Historic Trend Line -Fairly Valued range.

0.83

Karyopharm Therapeutics Inc. (KPTI) has a current PS of 0.83. The 5-year average PS is 2.25. The thresholds are as follows: Strongly Undervalued below -1.90, Undervalued between -1.90 and 0.17, Fairly Valued between 4.32 and 0.17, Overvalued between 4.32 and 6.39, and Strongly Overvalued above 6.39. The current Forward PS of 0.83 falls within the Historic Trend Line -Fairly Valued range.

-1.05

P/OCF

Karyopharm Therapeutics Inc. (KPTI) has a current P/OCF of -1.05. The 5-year average P/OCF is -2.50. The thresholds are as follows: Strongly Undervalued below -6.74, Undervalued between -6.74 and -4.62, Fairly Valued between -0.38 and -4.62, Overvalued between -0.38 and 1.74, and Strongly Overvalued above 1.74. The current Forward P/OCF of -1.05 falls within the Historic Trend Line -Fairly Valued range.

-1.10

P/FCF

Karyopharm Therapeutics Inc. (KPTI) has a current P/FCF of -1.10. The 5-year average P/FCF is -2.65. The thresholds are as follows: Strongly Undervalued below -7.71, Undervalued between -7.71 and -5.18, Fairly Valued between -0.12 and -5.18, Overvalued between -0.12 and 2.41, and Strongly Overvalued above 2.41. The current Forward P/FCF of -1.10 falls within the Historic Trend Line -Fairly Valued range.

Karyopharm Therapeutics Inc (KPTI) has a current Price-to-Book (P/B) ratio of -0.22. Compared to its 3-year average P/B ratio of -3.12 , the current P/B ratio is approximately -92.80% higher. Relative to its 5-year average P/B ratio of -3.16, the current P/B ratio is about -92.90% higher. Karyopharm Therapeutics Inc (KPTI) has a Forward Free Cash Flow (FCF) yield of approximately -75.35%. Compared to its 3-year average FCF yield of -121.35%, the current FCF yield is approximately -37.90% lower. Relative to its 5-year average FCF yield of -82.29% , the current FCF yield is about -8.43% lower.

-0.22

P/B

Median3y

-3.12

Median5y

-3.16

-75.35

FCF Yield

Median3y

-121.35

Median5y

-82.29

Competitors Valuation Multiple

The average P/S ratio for KPTI's competitors is 104.67, providing a benchmark for relative valuation. Karyopharm Therapeutics Inc Corp (KPTI) exhibits a P/S ratio of 0.83, which is -99.2% above the industry average. Given its robust revenue growth of 13.57%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of KPTI decreased by 31.49% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 38.78M to 44.04M.

The secondary factor is the Margin Expansion, contributed -9.06%to the performance.

Overall, the performance of KPTI in the past 1 year is driven by Revenue Growth. Which is more sustainable.

13.57%

38.78M → 44.04M

Revenue Growth

-9.06%

-82.70 → -75.21

Margin Expansion

-36.00%

-0.74 → -0.48

P/E Change

-31.49%

10.14 → 6.95

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Karyopharm Therapeutics Inc (KPTI) currently overvalued or undervalued?

What is Karyopharm Therapeutics Inc (KPTI) fair value?

KPTI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Karyopharm Therapeutics Inc (KPTI) is between 201.55 to 229.15 according to relative valuation methord.

How does KPTI's valuation metrics compare to the industry average?

The average P/S ratio for KPTI's competitors is 104.67, providing a benchmark for relative valuation. Karyopharm Therapeutics Inc Corp (KPTI) exhibits a P/S ratio of 0.83, which is -99.20% above the industry average. Given its robust revenue growth of 13.57%, this premium appears unsustainable.

What is the current P/B ratio for Karyopharm Therapeutics Inc (KPTI) as of Dec 15 2025?

As of Dec 15 2025, Karyopharm Therapeutics Inc (KPTI) has a P/B ratio of -0.22. This indicates that the market values KPTI at -0.22 times its book value.

What is the current FCF Yield for Karyopharm Therapeutics Inc (KPTI) as of Dec 15 2025?

As of Dec 15 2025, Karyopharm Therapeutics Inc (KPTI) has a FCF Yield of -75.35%. This means that for every dollar of Karyopharm Therapeutics Inc’s market capitalization, the company generates -75.35 cents in free cash flow.

What is the current Forward P/E ratio for Karyopharm Therapeutics Inc (KPTI) as of Dec 15 2025?

As of Dec 15 2025, Karyopharm Therapeutics Inc (KPTI) has a Forward P/E ratio of -0.96. This means the market is willing to pay $-0.96 for every dollar of Karyopharm Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Karyopharm Therapeutics Inc (KPTI) as of Dec 15 2025?

As of Dec 15 2025, Karyopharm Therapeutics Inc (KPTI) has a Forward P/S ratio of 0.83. This means the market is valuing KPTI at $0.83 for every dollar of expected revenue over the next 12 months.

KPTI Valuation